Managing MASH Without Invasiveness: A Patient-Centered Approach to Early Diagnosis and Weight-Based Intervention
Overview
In this CME/CE-accredited Interactive Case Challenge, explore a patient-centered approach to diagnosing and managing MASH using guideline-recommended noninvasive testing.
Learning objectives
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with metabolic-dysfunction associated steatohepatitis (MASH). Upon completion of this activity, participants should be able to:
- Employ guideline-recommended noninvasive testing to risk stratify, diagnose, and monitor patients with MASH.
- Apply strategies to achieve recommended weight loss to target the underlying pathophysiology of MASH.
Key dates
- Released date:
- Jul 14, 2025
- Expiration date:
- Jul 13, 2026
Sponsor
Provided by Clinical Care Options, LLC in partnership with AGA
Supporter acknowledgement
Supported by an educational grant from Novo Nordisk.Agenda
All times are Eastern.
Session Heading 1: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Session Heading 2: Lorem Ipsum Dolor sit Amet
10:00 a.m. - 5:00 p.m.
Session Sub-title 1
Person, PhD
10:00 - 11:00 a.m.
Session Sub-title 2
Person, PhD
11:00 - 12:00 midday
Session Sub-title 3
Person, PhD
12:00 - 1:00 p.m.
Course faculty and disclosures
Faculty
Scott L. Friedman, MD
Dean for Collaborative Research and Partnerships
Fishberg Professor of Medicine Professor of Pharmacologic Sciences Director, Institute for Liver Research Co-Director, Cancer Mechanisms Program, Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York
Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES
Abbott, Novo Nordisk, Xeris.